T1	intervention 58 67	Goserelin
T2	intervention 72 82	Raloxifene
T5	eligibility 109 163	Premenopausal Women at Increased Risk of Breast Cancer
T6	eligibility 497 538	Women at â‰¥30% lifetime risk breast cancer
T7	control 573 613	mammographic screening alone (C-Control)
T4	duration 755 762	2 years
T3	outcome-Measure 789 806	therapy adherence
T8	outcome-Measure 833 857	toxicity/quality of life
T9	outcome-Measure 859 881	change in bone density
T10	outcome-Measure 887 907	mammographic density
T11	No-of-participants 929 931	75
T12	intervention-value 999 1001	20
T13	intervention-participants 1005 1007	38
T14	intervention-value 1009 1012	52%
T15	outcome 1023 1059	completed the 2-year period of study
T16	control-value 1085 1087	27
T17	control-participants 1088 1090	37
T18	control-value 1092 1097	73.0%
T19	outcome 1100 1108	Dropouts
T20	outcome 1420 1445	Lumbar spine bone density
